Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada. Show more

#140, 14315 ? 118 AVENUE, EDMONTON, AB, CANADA, T5L 4S6, Edmonton, AB, T5L 4S6, USA

BIOTECHNOLOGY

HEALTHCARE

Market Cap

2.109B

52 Wk Range

$10.34 - $19.25

Previous Close

$15.85

Open

$15.70

Volume

1,050,211

Day Range

$15.42 - $15.94

Enterprise Value

1.729B

Cash

179.8M

Avg Qtr Burn

N/A

Insider Ownership

7.28%

Institutional Own.

59.00%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lupkynis (Voclosporin) Details Lupus nephritis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Aritinercept (AUR200) Details Autoimmune disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Voclosporin Details Focal segmental glomerulosclerosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Voclosporin Ophthalmic Solution Details Dry eye syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.